Research Center Adolescent Development at Utrecht University, Utrecht, The Netherlands.
J Child Psychol Psychiatry. 2011 Jan;52(1):80-90. doi: 10.1111/j.1469-7610.2010.02285.x.
Accumulating studies have demonstrated that the Screen for Child Anxiety Related Emotional Disorders (SCARED), a modern youth anxiety questionnaire with scales explicitly designed to map onto specific DSM-IV-TR anxiety disorders, has good psychometric properties for children and adolescents from various countries. However, no study has yet been conducted as to the overall strength of the psychometric properties found in these studies.
Studies were collected from the PsycINFO, PubMed, SSCI, SCI-Expanded, ERIC, and A&HCI databases from the year of the SCARED's first publication (1997) to the present. The inclusion criteria focused on all studies that examined the psychometric properties of the SCARED.
We retained 21 articles, reporting a total of 25 studies from predominantly Europe (Belgium, Germany, Italy, the Netherlands) and the USA, as well as South Africa and China, which matched our inclusion criteria. It was found that the psychometric properties were robust for the SCARED scales related to the symptoms of DSM-IV-TR anxiety disorders, that females scored significantly higher than males and that age had a moderating effect on male and female score differences.
This meta-analysis suggests that the SCARED can be utilized as a screening instrument for DSM-IV-TR anxiety disorder symptom dimensions for children and adolescents from various countries.
越来越多的研究表明,Screen for Child Anxiety Related Emotional Disorders(SCARED)是一种现代的青少年焦虑问卷,其量表专门设计用于映射特定的 DSM-IV-TR 焦虑障碍,具有良好的心理计量学特性,适用于来自不同国家的儿童和青少年。然而,目前还没有研究对这些研究中发现的心理计量学特性的整体强度进行评估。
从 1997 年 SCARED 首次发表之年至今,我们从 PsycINFO、PubMed、SSCI、SCI-Expanded、ERIC 和 A&HCI 数据库中收集了研究。纳入标准主要关注所有研究 SCARED 的心理计量学特性的研究。
我们保留了 21 篇文章,共报告了 25 项研究,这些研究主要来自欧洲(比利时、德国、意大利、荷兰)和美国,以及南非和中国,符合我们的纳入标准。研究结果表明,SCARED 量表与 DSM-IV-TR 焦虑障碍的症状相关,具有良好的心理计量学特性,女性得分显著高于男性,年龄对男女得分差异有调节作用。
这项荟萃分析表明,SCARED 可用于筛查来自不同国家的儿童和青少年的 DSM-IV-TR 焦虑障碍症状维度。